Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease

BACKGROUND: Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of plasma and structural MRI biomarkers, which are less costly and non-invasive,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Long, Das, Sandhitsu R., Wisse, Laura E. M., Ittyerah, Ranjit, de Flores, Robin, Shaw, Leslie M., Yushkevich, Paul A., Wolk, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088234/
https://www.ncbi.nlm.nih.gov/pubmed/37041649
http://dx.doi.org/10.1186/s13195-023-01210-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088234/
https://www.ncbi.nlm.nih.gov/pubmed/37041649
http://dx.doi.org/10.1186/s13195-023-01210-z

Ejemplares similares